Mirum Pharmaceuticals, Inc. · NASDAQ:MIRM
Mirum Pharmaceuticals — Merger or Acquisition (July 2023)
14 slides from Mirum Pharmaceuticals's merger presentation, Jul 17, 2023
Slide 1: Mirum Pharmaceuticals: Transforming Lives in Rare Disease
Mirum Pharmaceuticals: Transforming Lives in Rare Disease J u l y 2 0 2 3
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in
Slide 3: Disclaimers
Disclaimers This confidential presentation (“Presentation”) is for informational purposes only and is being provided to interested parties solely in their capacity as potential investors for the purpose of evaluating a potential private offering of securities to occur concurrently with a potential b
Slide 4: Leader in Rare Liver Disease: 2023 Goals
Leader in Rare Liver Disease: 2023 Goals I N D U S T R Y L E A D I N G T E A M , D E L I V E R I N G R E M A R K A B L E T R E AT M E N T S TO PAT I E N T S I N N E E D W O R L D W I D E Build on US LIVMARLI ALGS Establish LIVMARLI in Additional Commercial Success Pediatric Cholestatic Settings Laun
Slide 5: Potential Acquisition of Travere's Bile Acid Product Portfolio
Potential Acquisition of Travere’s Bile Acid Product Portfolio DEAL RATIONALE: • Solidifies Mirum’s leadership on pediatric hepatology/GI Significant Revenue – Accelerates LIVMARLI growth & Cash Flow Expected – Bile Acid portfolio addressing multiple high need settings $103 Million 2022 NET REVENUE
Slide 6: Mirum Proven Execution Track Record, Delivering Value
Mirum Proven Execution Track Record, Delivering Value EFFICIENT BUSINESS MODEL GENERATING TOPLINE GROWTH WITH MULTIPLE NEAR-TERM VALUE CATALYSTS LIVMARLI – approved for cholestatic Robust Pipeline Opportunity Strong Foundation for Growth pruritus in Alagille Syndrome (ALGS) with with a Validated Sci
Slide 7: Commercial-Stage with Pipeline of Growth Opportunities
Commercial-Stage with Pipeline of Growth Opportunities 3 APPROVED RARE DISEASE PRODUCTS, 5 ADDITIONAL INDICATIONS IN DEVELOPMENT IN HIGH-NEED ORPHAN INDICATIONS Alagille syndrome* Bile acid portfolio Preclinical Phase 1 Phase 2b/Phase 3 Approved Progressive Familial FDA PDUFA Dec 13, 2023 LIVMARLI I
Slide 8: Establishing Leadership on the Rare Pediatric Liver Call Point
Establishing Leadership on the Rare Pediatric Liver Call Point >300 ALGS PATIENTS TREATED (US-COMMERCIAL) SUBSTANTIALLY ALL KEY ACCOUNTS HAVE PRESCRIBED US Pediatric Liver Prescriber Landscape 50 Major Accounts 180 Total Account Universe Standard of Care for Bile Acid Synthesis Disorders and CTX Bra
Slide 9: Mirum Positioned as a Partner from the Start of the Patient Journey
Mirum Positioned as a Partner from the Start of the Patient Journey Patient Identification & Diagnosis Access & Awareness Treatment Options Free, Mirum sponsored & branded A Customer-Focused Approach to Drive Broad portfolio addressing spectrum of cholestasis genetic testing panel Uptake & Retention
Slide 10: Building Leadership to Accelerate Livmarli Performance
Building Leadership to Accelerate Livmarli Performance Significant headroom remains to grow Livmarli in ALGS and new indications in US >$1 Billion LIVMARLI US Opportunity Total Net Product Sales Strengthened by Bile Acid Product Acquisition Continued U.S. & International growth* US business position
Slide 11: A Mature, Profitable Business With Strong Commercial Synergies
A Mature, Profitable Business With Strong Commercial Synergies Steady Growth in Bile Acid Portfolio Bile Acid Portfolio Indications Net Product Sales US Prevalence Overview 120 Bile Acid Synthesis Group of genetic disorders with Disorders (BASD) abnormal bile acid production 100 103 96 ~200-300 89 G
Slide 12: RESTORE Phase 3: Potentially NDA enabling for CTX, Orphan Exclusivity
RESTORE Phase 3: Potentially NDA enabling for CTX, Orphan Exclusivity Top-line data in H2:2023 Adult Study (age 16+), n=12* Primary Endpoint • Change from baseline in Log-transformed urine total 23S-pentol at the end of each double- Follow-up blind (DB) treatment period (30 days) Secondary Endpoints
Slide 13: A Compelling Transaction to Reinforce Mirum's Rare Disease Leadership
A Compelling Transaction to Reinforce Mirum’s Rare Disease Leadership New programs elevate and advance Mirum’s strategy • Adds commercialized medicines for pediatric hepatology • Enhances the growth of LIVMARLI • Expands operating and financial scale • ~$220M combined run rate revenue, expect cash f
Slide 14: Thank you
Thank you 14
Mirum Pharmaceuticals — Merger or Acquisition (July 2023) on 6ix